Payment overview · 2025
General Payments
$189,343.77
372 reported records · 24 companies
Healthcare provider profile · identity verified
Noah Lee, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · OAKLAND PARK, FL · NPI 1275559106
Verified facts
What the public records show
CMS Open Payments records show Noah Lee, D.O. received $189,343.77 in general payments during 2025 across 372 reported records.
ViiV Healthcare Company accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Delstrigo, Descovy, Dovato, Farxiga, Gemtesa, Jardiance, Mytesi, Ozempic, Pifeltro, Rexulti, Rukobia, Rybelsus, Serostim.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Sunosi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 759 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 445 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Delstrigo by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Pifeltro by this doctor in 2024.
Napo Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mytesi as an associated drug or biological on 1178 records involving 562 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mytesi by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Relistor by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $76,927.30 | 40.6% | 123 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $64,346.03 | 34.0% | 91 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $15,836.83 | 8.4% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $12,700.14 | 6.7% | 29 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $9,811.31 | 5.2% | 17 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $8,093.13 | 4.3% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $317.56 | 0.2% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $295.12 | 0.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $268.99 | 0.1% | 15 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $184.70 | 0.1% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $95.65 | 0.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.58 | 0.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.61 | 0.0% | 4 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.31 | 0.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.53 | 0.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.78 | 0.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.30 | 0.0% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.61 | 0.0% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $29.58 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.80 | 0.0% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $17.13 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.63 | 0.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.33 | 0.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.82 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $131,882.50 | 49 |
| Travel and Lodging | $17,523.43 | 35 |
| Consulting Fee | $15,476.00 | 3 |
| Food and Beverage | $10,945.84 | 280 |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,631.00 | 2 |
| Honoraria | $5,885.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $39,736.48 | 34 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $29,998.37 | 27 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $22,156.77 | 20 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $14,935.67 | 17 | 2025 |
Source payment records
|
|||||
| Serostim Normalized: serostim |
Drug | EMD Serono, Inc. | $13,367.89 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $12,700.14 | 29 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $11,681.09 | 16 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $9,811.31 | 17 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $9,081.44 | 9 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $8,093.13 | 16 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $453.94 | 9 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $393.48 | 27 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $317.56 | 22 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $249.80 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $167.57 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.66 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.92 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $109.47 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $109.46 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $109.25 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.47 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $68.58 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.61 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.35 | 4 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $57.31 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $34.61 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| Sunlenca Normalized: sunlenca |
Drug | Gilead Sciences, Inc. | $16.86 | 8 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 759 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DELSTRIGO delstrigo |
2025 | Delstrigo | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Descovy descovy |
2025 | Descovy | 2024 | 445 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 172 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mytesi mytesi |
2025 | Mytesi | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 199 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Serostim serostim |
2025 | Serostim | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
115 | 16 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
759 | 79 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
445 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
136 | 13 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
199 | 22 |
| Napo Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Mytesi open payments reported associated product |
CMS Open Payments — General Payments 1178 supporting records · 562 recipient NPIs · example record 1223618503 |
Mytesi · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 36 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
172 | 24 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 759 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 687 | 147 |
| Alprazolam | Alprazolam | 578 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 532 | 124 |
| Descovy | Emtricitabine/Tenofov Alafenam | 445 | 54 |
| Testosterone Cypionate | Testosterone Cypionate | 392 | 91 |
| Lisinopril | Lisinopril | 377 | 76 |
| Omeprazole | Omeprazole | 342 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 333 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 62 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 254 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 252 | 58 |
| Valacyclovir | Valacyclovir Hcl | 237 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 49 |
| Tivicay | Dolutegravir Sodium | 229 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 54 |
| Gabapentin | Gabapentin | 210 | 41 |
| Bupropion Xl | Bupropion Hcl | 207 | 35 |
| Losartan Potassium | Losartan Potassium | 205 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 204 | 51 |
| Pifeltro | Doravirine | 199 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 35 |
| Dovato | Dolutegravir Sodium/Lamivudine | 172 | 24 |
| Prezcobix | Darunavir/Cobicistat | 158 | 18 |
| Trazodone Hcl | Trazodone Hcl | 157 | 32 |
| Clonazepam | Clonazepam | 151 | 28 |
| Finasteride | Finasteride | 150 | 36 |
| Anastrozole | Anastrozole | 149 | 35 |
| Lorazepam | Lorazepam | 139 | 24 |
| Temazepam | Temazepam | 137 | 21 |
| Isentress | Raltegravir Potassium | 136 | 13 |
| Meloxicam | Meloxicam | 136 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 130 | 53 |
| Ezetimibe | Ezetimibe | 127 | 28 |
| Ozempic | Semaglutide | 126 | 19 |
| Simvastatin | Simvastatin | 126 | 34 |
| Acyclovir | Acyclovir | 123 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 29 |
| Famotidine | Famotidine | 121 | 30 |
| Metformin Hcl | Metformin Hcl | 120 | 31 |
| Atenolol | Atenolol | 116 | 23 |
| Serostim | Somatropin | 115 | 16 |
| Testosterone | Testosterone | 114 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 25 |
| Azithromycin | Azithromycin | 109 | 83 |
| Diazepam | Diazepam | 106 | 20 |
| Etravirine | Etravirine | 106 | 11 |
| Xarelto | Rivaroxaban | 104 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 28 |
| Farxiga | Dapagliflozin Propanediol | 100 | 18 |
| Furosemide | Furosemide | 91 | 27 |
| Repatha Sureclick | Evolocumab | 91 | 18 |
| Allopurinol | Allopurinol | 89 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 17 |
| Eliquis | Apixaban | 81 | 17 |
| Metformin Hcl Er | Metformin Hcl | 79 | 22 |
| Montelukast Sodium | Montelukast Sodium | 78 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 78 | 17 |
| Vascepa | Icosapent Ethyl | 78 | 13 |
| Tadalafil | Tadalafil | 76 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 15 |
| Cefdinir | Cefdinir | 74 | 62 |
| Sertraline Hcl | Sertraline Hcl | 74 | 16 |
| Carvedilol | Carvedilol | 73 | 19 |
| Egrifta Sv | Tesamorelin Acetate | 73 | suppressed |
| Potassium Chloride | Potassium Chloride | 73 | 14 |
| Rukobia | Fostemsavir Tromethamine | 71 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 67 | 14 |
| Eszopiclone | Eszopiclone | 66 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 23 |
| Pregabalin | Pregabalin | 65 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 61 | 13 |
| Baclofen | Baclofen | 59 | 12 |
| Belsomra | Suvorexant | 58 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 58 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Ketoconazole | Ketoconazole | 52 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 51 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 51 | suppressed |
| Dutasteride | Dutasteride | 50 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 50 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 48 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 48 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 48 | suppressed |
| Maraviroc | Maraviroc | 47 | suppressed |
| Kerendia | Finerenone | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 36 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Movantik | Naloxegol Oxalate | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 15 |
| Tramadol Hcl | Tramadol Hcl | 43 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 43 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Darunavir | Darunavir | 40 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Nevirapine | Nevirapine | 39 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 36 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 16 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Praluent Pen | Alirocumab | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Mytesi | Crofelemer | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 16 |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Loperamide | Loperamide Hcl | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 30 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 30 | suppressed |
| Isentress Hd | Raltegravir Potassium | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ritonavir | Ritonavir | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Dronabinol | Dronabinol | 27 | suppressed |
| Armodafinil | Armodafinil | 26 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 14 |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Emtricitabine | Emtricitabine | 24 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Fetzima | Levomilnacipran Hcl | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Triazolam | Triazolam | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Lamivudine-Zidovudine | Lamivudine/Zidovudine | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Sunosi | Solriamfetol Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Entecavir | Entecavir | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nevirapine Er | Nevirapine | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Xyosted | Testosterone Enanthate | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Tinidazole | Tinidazole | 15 | 12 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | 14 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 13 | suppressed |
| Depakote | Divalproex Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Relistor | Methylnaltrexone Bromide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Tretinoin | Tretinoin | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Erythromycin-Benzoyl Peroxide | Erythromycin/Benzoyl Peroxide | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Testosterone Enanthate | Testosterone Enanthate | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $189,343.77 · 372 records | ViiV Healthcare Company | AIRSUPRA, APRETUDE, APTIMA, AREXVY, Auvelity, BREZTRI, Biktarvy, CABENUVA, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, DELSTRIGO, DOVATO, Descovy, EGRIFTA, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, Mytesi, NURTEC ODT, OTEZLA, Ozempic, PIFELTRO, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, RUKOBIA, Rybelsus, SHINGRIX, Serostim, Sunlenca, TERIPARATIDE, TROGARZO, Tlando, UBRELVY, Wegovy, XIFAXAN, Yeztugo, ZAVZPRET | 28 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error